Vote Scores
Filings read through

NewAmsterdam Pharma Company N.V.: how funds voted at the meeting of 2 Jun 2026

Ticker
NAMS
Meeting
Season
year to 30 June 2026
Filers reporting
268
Ballot items
7

268 filers on Form N-PX reported votes at the NewAmsterdam Pharma Company N.V. meeting of 2 Jun 2026. The records fall into 7 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 80.6% of the reported votes are for. 36 filers withheld from or voted against at least one nominee.

    275 vote records from 94 filers. 1 of the 92 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 29 fund families
    • For 20
    • Split or no vote 9
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    374 vote records from 266 filers. 57 of the 248 filers that marked the item voted against management. 18 filers gave no management mark.

    • Positions of 36 fund families
    • For 29
    • Against 7
    • Against management 7
  3. Item 3: Audit-related items (auditor ratification)

    262 vote records from 94 filers. 1 of the 92 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 29 fund families
    • For 29
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    275 vote records from 93 filers. 64 of the 91 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 29 fund families
    • For 4
    • Against 25
    • Against management 25
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    134 vote records from 88 filers. 2 of the 86 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 28 fund families
    • For 28
  6. Item 6: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    262 vote records from 93 filers. 1 of the 91 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 29 fund families
    • For 29
  7. Item 7: OTHER: management items

    The company's items in this category are shown together, because filers word and number them differently.

    17 vote records from 9 filers. 0 of the 9 filers that marked the item voted against management.

    • Positions of one fund family
    • For 1

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at NewAmsterdam Pharma Company N.V., meeting of 2 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinForFor
AllspringForFor
American CenturyAgainst, against managementFor
BlackRock and iSharesForFor
BNY MellonAgainst, against managementFor
Brighthouse FundsForFor
Capital Group and American FundsForFor
Charles SchwabForNo report
Columbia ThreadneedleForFor
EquitableForFor
Federated HermesForFor
FidelityForFor
First TrustForFor
Franklin TempletonForFor
Global XAgainst, against managementFor
Goldman SachsForFor
Harbor FundsForFor
Hartford FundsForFor
InvescoAgainst, against managementFor
J.P. MorganForFor
Janus HendersonForNo report
John Hancock and ManulifeForNo report
Lord AbbettForFor
Morgan Stanley, Eaton Vance and CalvertForFor
Natixis and Loomis SaylesForNo report
Northern Trust and FlexSharesForNo report
Nuveen and TIAAForNo report
Pacific Life fundsForFor
PGIM and PrudentialAgainst, against managementFor
PrincipalForFor
ProShares and ProFundsForFor
Russell InvestmentsAgainst, against managementFor
SEIAgainst, against managementNo report
State Street and SPDRForFor
VanguardForFor
Victory CapitalForFor

Questions

How many filers reported votes at the NewAmsterdam Pharma Company N.V. meeting?
268 Form N-PX filers reported votes at the meeting of 2 Jun 2026. On say-on-pay, 57 of 248 filers that marked the item voted against management (23.0%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. NewAmsterdam Pharma Company N.V. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list NewAmsterdam Pharma Company N.V. with a meeting date within three days of 2 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .